Clinical Trial Update: Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial is evaluating durvalumab with or without lenalidomide in patients with relapsed or refractory cutaneous or peripheral T-cell lymphoma…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous T-cell Non-hodgkin Lymphoma
• Folliculotropic Mycosis Fungoides
• Mature T- and Nk-cell Non-hodgkin Lymphoma
• Mycosis Fungoides
• Peripheral T-cell Lymphoma Not Otherwise Specified
• Sezary Syndrome

Drugs mentioned

• Durvalumab (durvalumab)
• Lenalidomide (lenalidomide)

Snippet

Sponsor: City of Hope Medical Center | Conditions: Folliculotropic Mycosis Fungoides, Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING